These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 20522598)

  • 21. Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy.
    Theilade S; Lajer M; Jorsal A; Tarnow L; Parving HH; Rossing P
    Diabet Med; 2012 Mar; 29(3):337-44. PubMed ID: 21988672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study.
    Al Rifai M; Schneider AL; Alonso A; Maruthur N; Parrinello CM; Astor BC; Hoogeveen RC; Soliman EZ; Chen LY; Ballantyne CM; Halushka MK; Selvin E
    J Diabetes Complications; 2015 Mar; 29(2):180-5. PubMed ID: 25499973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.
    Thomas MC; Woodward M; Neal B; Li Q; Pickering R; Marre M; Williams B; Perkovic V; Cooper ME; Zoungas S; Chalmers J; Hillis GS;
    Diabetes Care; 2015 Oct; 38(10):1891-7. PubMed ID: 26253728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes.
    Wannamethee SG; Welsh P; Papacosta O; Ellins EA; Halcox JPJ; Whincup PH; Sattar N
    Atherosclerosis; 2017 Sep; 264():36-43. PubMed ID: 28759844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating Advanced Glycation End Products and Their Soluble Receptors in Relation to All-Cause and Cardiovascular Mortality: A Systematic Review and Meta-analysis of Prospective Observational Studies.
    Sharifi-Zahabi E; Sharafabad FH; Abdollahzad H; Malekahmadi M; Rad NB
    Adv Nutr; 2021 Dec; 12(6):2157-2171. PubMed ID: 34139010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between advanced glycation end products, their soluble receptor, and mortality in the general population: Results from the CARLA study.
    Ebert H; Lacruz ME; Kluttig A; Simm A; Greiser KH; Tiller D; Kartschmit N; Mikolajczyk R
    Exp Gerontol; 2020 Mar; 131():110815. PubMed ID: 31857132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients.
    Assiri AMA; Kamel HFM; ALrefai AA
    Med Sci (Basel); 2018 May; 6(2):. PubMed ID: 29789493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes.
    Wadén JM; Dahlström EH; Elonen N; Thorn LM; Wadén J; Sandholm N; Forsblom C; Groop PH;
    Diabetologia; 2019 Jul; 62(7):1268-1274. PubMed ID: 31127314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. sRAGE and risk of diabetes, cardiovascular disease, and death.
    Selvin E; Halushka MK; Rawlings AM; Hoogeveen RC; Ballantyne CM; Coresh J; Astor BC
    Diabetes; 2013 Jun; 62(6):2116-21. PubMed ID: 23396398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
    Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A
    Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function.
    Kajikawa M; Nakashima A; Fujimura N; Maruhashi T; Iwamoto Y; Iwamoto A; Matsumoto T; Oda N; Hidaka T; Kihara Y; Chayama K; Goto C; Aibara Y; Noma K; Takeuchi M; Matsui T; Yamagishi S; Higashi Y
    Diabetes Care; 2015 Jan; 38(1):119-25. PubMed ID: 25336748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene.
    Kanková K; Kalousová M; Hertlová M; Krusová D; Olsovský J; Zima T
    Arch Physiol Biochem; 2008 Apr; 114(2):111-9. PubMed ID: 18615900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.
    Chiang KH; Huang PH; Huang SS; Wu TC; Chen JW; Lin SJ
    Coron Artery Dis; 2009 Jun; 20(4):267-73. PubMed ID: 19440065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced glycation end products (AGEs) and their soluble receptors (sRAGE) as early predictors of reno-vascular complications in patients with uncontrolled type 2 diabetes mellitus.
    Farhan SS; Hussain SA
    Diabetes Metab Syndr; 2019; 13(4):2457-2461. PubMed ID: 31405660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
    Lajer M; Tarnow I; Michelson AD; Jorsal A; Frelinger AL; Parving HH; Rossing P; Tarnow L
    Platelets; 2010; 21(7):525-32. PubMed ID: 20701458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women.
    Semba RD; Ferrucci L; Fink JC; Sun K; Beck J; Dalal M; Guralnik JM; Fried LP
    Am J Kidney Dis; 2009 Jan; 53(1):51-8. PubMed ID: 18789567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.
    Cheng Y; Zhong J; Xiang Y; Zeng F; Cai D; Zhao L
    Clin Interv Aging; 2014; 9():1981-6. PubMed ID: 25429209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women.
    Semba RD; Ferrucci L; Sun K; Beck J; Dalal M; Varadhan R; Walston J; Guralnik JM; Fried LP
    Aging Clin Exp Res; 2009 Apr; 21(2):182-90. PubMed ID: 19448391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults.
    Davis KE; Prasad C; Vijayagopal P; Juma S; Imrhan V
    Nutr Res; 2014 Jun; 34(6):478-85. PubMed ID: 25026914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.